Quantcast

Latest Anthrax Stories

2014-09-22 12:31:25

PINE BROOK, N.J., Sept. 22, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development for the treatment of inhalational anthrax and data from these studies support the safety and tolerability of the antitoxin when administered intravenously...

2014-09-19 08:25:40

PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute...

2014-09-10 08:32:30

ANNAPOLIS, Md., Sept. 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the...

2014-09-09 08:33:14

ANNAPOLIS, Md., Sept. 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax(®) anthrax vaccine program were presented at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. In a poster presentation entitled, "Enhanced Next Generation rPA Vaccine Induces Immunogenicity and Efficacy at Least Equivalent to AVA in the New Zealand White (NZW) Rabbit Model for Anthrax," Dr....

2014-08-11 08:28:46

PRINCETON, N.J., Aug. 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014. Soligenix's revenues for the quarter and six months ended June 30,...

2014-08-01 08:26:07

Awarded $2.1 million in additional funding PRINCETON, N.J., Aug. 1, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to...

antibiotic resistance
2014-07-24 05:43:55

redOrbit Staff & Wire Reports - Your Universe Online Antibiotic resistance could bring about the “next pandemic,” turning run-of-the-mill disease-causing bacteria into nearly untreatable illnesses, the US Centers for Disease Control and Prevention (CDC) warned on Tuesday. Speaking at a National Press Club event, CDC director Tom Frieden said that the common use of antibiotics and other anti-microbial agents over the past 70 years has caused some pathogens to mutate and become...

2014-07-09 08:20:35

Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., July 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to...

2014-07-02 23:12:01

New York personal injury lawyer David Perecman of The Perecman Firm weighs in on the anthrax scare at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. New York, New York (PRWEB) July 02, 2014 In June, over 80 Atlanta-based workers for the U.S. Centers for Disease Control and Prevention (CDC) were potentially exposed to anthrax. A highly secure lab accidentally sent a batch of live anthrax to a less-secure laboratory that was not equipped to handle the live...

CDC Workers Exposed To Anthrax
2014-06-21 07:51:52

Alan McStravick for redOrbit.com - Your Universe Online The Centers for Disease Control and Prevention (CDC) is one of those government agencies that is almost universally regarded as entirely competent and worthy of having the complete trust of the American public. This stellar reputation may, in fact, be wholly unwarranted. It was reported Thursday that as many as 86 government scientists, researchers and employees were exposed to the potentially lethal live form of the bacterium...


Latest Anthrax Reference Libraries

11_ca5cd45b16f3d4936fde0520fef6557b
2011-04-14 14:43:25

Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2µm and a length of 3-5µm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...

More Articles (1 articles) »
Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related